SecBot SecBot
Biotech Drug Report Generated Nov 7, 2026

praliciguat

AKBA·Akebia Therapeutics, Inc.
NEUTRAL
Drug Impact Rating3/10
Trial phase
Phase 2
Time to market
Praliciguat is in Phase 2 testing with estimated trial completion in January 2028. If successful, a Phase 3 program would be needed before any FDA submission, placing potential approval several years away at best.
Why 3/10
Praliciguat has no scheduled binary catalyst within the next ~12 months. The Phase 2 FSGS trial is still enrolling with estimated completion in January 2028, and management provided no data readout timeline on the Q3 2026 earnings call. The drug is a small, early-stage pipeline component; Akebia's primary value driver is its approved anemia drug Vafseo (vadadustat).
Actionable Insight NEUTRAL

Praliciguat has no near-term binary catalyst. The Phase 2 FSGS trial is still enrolling with estimated completion in January 2028, and Akebia's Q3 2026 earnings call provided no data timeline for this asset. Watch for any future update on enrollment completion or a topline data readout timeline, but praliciguat is unlikely to be a meaningful stock-moving catalyst for AKBA in the next 12 months. The stock's near-term drivers are Vafseo commercial execution and the Nasdaq minimum bid price compliance situation.

Price Chart

Loading chart...

Executive Summary

Praliciguat (IW-1973) is an oral, once-daily soluble guanylate cyclase (sGC) stimulator being developed by Akebia Therapeutics (NASDAQ: AKBA) for focal segmental glomerulosclerosis (FSGS), a rare kidney disease with no FDA-approved therapies. Akebia licensed the drug from Cyclerion Therapeutics in 2021 after prior Phase 2 studies in heart failure and diabetic kidney disease showed no clear clinical benefit. The drug is currently in a Phase 2 trial (NCT07268638) that began enrolling in December 2025, with first patient dosed in January 2026 and estimated completion in January 2028. Akebia presented a trial-in-progress poster at ASN Kidney Week in October 2026. Praliciguat is a small, early-stage pipeline component for Akebia; the company's primary value driver is its approved anemia drug Vafseo (vadadustat). No data readout timeline has been provided for praliciguat.

How It Works

Praliciguat is a small molecule that stimulates an enzyme called soluble guanylate cyclase (sGC), which amplifies the body's natural nitric oxide signaling pathway. This pathway helps blood vessels relax, reduces inflammation, and protects kidney cells from injury. By boosting this signaling, the drug aims to reduce protein leakage in the urine and preserve kidney function in patients with FSGS, a rare kidney disease where the filtering units of the kidney are scarred.

Trial Status

Praliciguat is in a Phase 2, randomized, double-blind, placebo-controlled, multicenter trial (NCT07268638) for focal segmental glomerulosclerosis (FSGS). The trial aims to enroll approximately 60 patients who are randomized 1:1 to praliciguat or placebo for a 24-week treatment period, followed by an open-label extension. The primary endpoint is change in urine protein-to-creatinine ratio. The trial began in December 2025, with first patient dosed in January 2026. As of the Q3 2026 earnings call (November 5, 2026), the company confirmed the trial is enrolling but provided no data readout timeline. Estimated primary completion is January 2028. Akebia presented a trial-in-progress poster at ASN Kidney Week in October 2026.

The Two-Sided Case

▲ Bull Case3
FSGS is a rare kidney disease with no FDA-approved therapies, representing an unmet medical need and potential orphan drug opportunity if praliciguat succeeds.
Praliciguat's mechanism (sGC stimulation) has a well-understood biological rationale for kidney protection, and prior Phase 1/2 studies showed an acceptable safety profile with no significant safety issues.
Akebia has a commercial infrastructure from Vafseo that could support a future FSGS launch, and the company is investing in the rare kidney disease pipeline with R&D spending increasing to $16.2 million in Q3 2026.
▼ Bear Case4
Praliciguat previously failed to show clear clinical benefit in Phase 2 trials for heart failure with preserved ejection fraction (HFpEF) and diabetic kidney disease, raising questions about its efficacy.
The Phase 2 FSGS trial is early-stage (just began enrolling in December 2025) with estimated completion not until January 2028, meaning no data catalyst for at least 12 months.
Akebia's market cap is only ~$111 million and the stock has fallen 80% in the past year, with the company facing a Nasdaq minimum bid price deficiency notice, creating financial overhang.
Several large institutional holders (State Street, Bank of America, Citigroup) significantly trimmed or exited their AKBA positions in Q2 2026, signaling caution.

Upcoming Catalysts

  • Phase 2 FSGS trial enrollment completion update (no timeline provided)
  • Potential future topline data readout from Phase 2 FSGS trial (estimated trial completion January 2028, no specific data timeline announced)

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Akebia Therapeutics, Inc. PRESS-RELEASE AKBA ·Originating report

Sources · 9

Hover a chip for the title
1 ir.akebia.com2 clinicaltrials.gov3 asn-online.org4 biospace.com5 marketbeat.com6 ir.akebia.com7 adisinsight.springer.com8 synapse-patsnap-com.sutd.idm.oclc.org9 stockanalysis.com